BiqqieSmalls
Established Member
- Reaction score
- 2
There could be a million reasons why they gave up on Setipiprant. Perhaps they'd make much more money off the sale of the rights of Set instead of going through years of the FDA process and could then use that capital towards other therapies. There WILL be something coming. Look at all the competition there is. This is an unsaturated market with billions to be made. If you don't think another significant treatment or cure will come relatively soon, I advise you to read about economics.You know who else I think knows something and is keeping quiet? Actelon (or whatever) the company that previously owned SET. They were testing it for asthma, and gave up on it because it was not strong enough, but I'm sure that they would have maybe noticed something in the hair department if it was working right?